Skip to main
MRTX
MRTX logo

Mirati Therapeutics (MRTX) Stock Forecast & Price Target

Mirati Therapeutics (MRTX) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 16%
Buy 28%
Hold 56%
Sell 0%
Strong Sell 0%
Mirati Therapeutics (MRTX) has been analyzed by 25 analysts, with a consensus rating of Buy. 16% of analysts recommend a Strong Buy, 28% recommend Buy, 56% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mirati Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mirati Therapeutics (MRTX) Forecast

Analysts have given Mirati Therapeutics (MRTX) a Buy based on their latest research and market trends.

According to 25 analysts, Mirati Therapeutics (MRTX) has a Buy consensus rating as of Aug 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $82.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $82.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mirati Therapeutics (MRTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.